The 2022 Volvo XC90 is now deep into its second generation, having been on sale since 2015, but we expect it will see some major changes for its upcoming third generation EV reinvention debuting soon.

If you are wondering what to make of Embla Medical hf right now, you are definitely not alone. The stock has caught the attention of investors who are keen on understanding its next move, especially ...

Tim Hoffmann joined Icelandic medical device company Embla Medical in 2021, and three years later he was recognized with the Rising Star Award at the Business Journal’s 17th annual CFO of the Year ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Next year, Volvo Cars will unveil the all-electric successor to the XC90 SUV, which may be called Embla judging by a trademark application with the EUIPO. Previewed by last year's Concept Recharge, ...

Mere days ago, the premium Swedish automaker finally revealed some details regarding the third generation of its flagship SUV. Now, of course, it already travels across the CGI roads of the virtual ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Embla Medical hf (CPSE:EMBLA) is in focus after reporting ...

SAN CARLOS, Calif.--(BUSINESS WIRE)--Natus Medical Incorporated (Nasdaq:BABY) today announced that it has acquired Embla Systems LLC, a leader in the development, manufacturing, and sales of devices ...

The current Volvo XC90 is the second generation of the car, which has been with us since the 2015 model year and, as such, getting a bit long in the tooth, even after a facelift last year. However, ...

Volvo’s future flagship will not be called XC90 anymore. As we told our readers in November 2021, it will very likely be named Embla. The Swedish carmaker may have given us the best glimpse yet on the ...

Sveinn Sölvason, President and CEO, comments: "Sales in Q2 2025 amounted to USD 232 million, representing 7% reported growth, of which 5% was organic. Growth was strong in the Prosthetics & Neuro ...